News | Contrast Media | September 11, 2015

Ultrasound Pilot Study Shows Positive Results for Treatment of Pancreatic Cancer

Microbubble contrast agent can improve tumor absorption of cancer drugs

ultrasound, microbubbles, delivery, absorption, drugs, pancreatic cancer, ICUS

September 11, 2015 — Tiny gas microbubbles can enhance the delivery and absorption of cancer drugs in patients with advanced pancreatic cancer, according to a new pilot study. The study was described at the International Contrast Ultrasound Society (ICUS) annual conference in Chicago.

One year after their last treatment cycle, two of 10 patients are still alive. 74 percent of pancreatic cancer patients die within the first year of diagnosis. The average life expectancy after diagnosis with metastic pancreatic cancer is just three to six months.

"Our early findings suggested that commercially-available ultrasound microbubbles, combined with a standard chemotherapy drug, might prolong survival in pancreatic cancer patients," according to Odd Helge Gilja, M.D., head of National Centre of Ultrasound in Gastroenterology at Haukeland University Hospital, in Bergen, Norway.

The pilot study included 10 patients with inoperable tumors, and preliminary results in 2014 showed that tumor size was reduced or growth was slowed in the patients, according to Gilja. "The patients treated with ultrasound sonoporation were able to undergo significantly more treatment cycles than those receiving standard chemotherapy. Additional studies are planned to confirm and potentially extend the results," he said.

"The findings are extremely exciting because this study appears to represent the first time ultrasound microbubbles have been used in patients for drug delivery," according to Steven Feinstein, M.D., co-president of ICUS and a professor of medicine at Rush University, Chicago. "If further studies confirm the Bergen findings, ultrasound microbubbles could prove to be an innovative platform option for delivery of drugs and genes to treat other cancers and a wide variety of medical abnormalities throughout the body," he said.

Gilja reported that all 10 patients who participated in the pilot Phase I study received an infusion of a standard chemotherapy drug, gemcitabine, followed by an infusion of a microbubble contrast agent. A customized commercial ultrasound scanner was then used to confirm the presence of the microbubbles in the vicinity of the tumor and to induce "sonoporation," a transient opening and resealing of cell membranes to allow for enhanced delivery and absorption of the cancer drug. Tumor sizes were confirmed by computed tomography (CT) imaging, according to Gilja.

Three ultrasound contrast agents — Definity (Lantheus Medical Imaging), Optison (GE Healthcare) and Lumason (Bracco Diagnostics) — are available in the United States but are approved by the U.S. Food and Drug Administration for cardiac imaging only.

For more information: www.icus-society.org

Related Content

Triton College Launching Vascular Technology in Sonography Certificate Program
News | Ultrasound Imaging | January 09, 2019
Starting in spring 2019, Triton College’s Vascular Technology in Sonography Certificate Program will help working...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Videos | Artificial Intelligence | December 21, 2018
Enhao Gong, Ph.D., founder of Subtle Medical, an artificial intelligence (AI) company that develops products to help
Fujifilm SonoSite Showcases Point-of-care Ultrasound Portfolio At RSNA 2018
News | Ultrasound Imaging | December 20, 2018
Fujifilm SonoSite Inc. recently present its complete portfolio of point-of-care ultrasound (POCUS) systems at the 2018...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...
Sponsored Content | Videos | Ultrasound Imaging | December 14, 2018
Based on Mindray’s Living Technology, the Resona 7 (Sapphire), ZS3 (Diamond) and TE7 (Crystal) new ultrasound upgrades...
Guerbet Showcases Diagnostic and Interventional Imaging Solutions at RSNA 2018
News | Interventional Radiology | December 12, 2018
Guerbet LLC USA highlighted new and next-level product offerings and partnerships in contrast media, injectors,...
Hitachi Medical Systems Europe Introduces Third-Generation Intelligent Vector Flow Mapping
News | Cardiovascular Ultrasound | December 07, 2018
Hitachi Medical Systems Europe introduced what it calls the next level of intelligent Vector Flow Mapping (iVFM) at...
Guerbet Launches Multi-Use OptiVantage Contrast Media Injector in Europe
Technology | Contrast Media Injectors | December 05, 2018
Contrast agent company Guerbet recently announced that the OptiVantage multi-use contrast media injector is now CE...
GE Healthcare Unveils New Applications and Smart Devices Built on Edison Platform
Technology | Artificial Intelligence | December 05, 2018
GE Healthcare recently announced new applications and smart devices built on Edison – a platform that helps accelerate...